Colorectal Cancer (CRC) Clinical Trials

43 recruiting

Colorectal Cancer (CRC) Trials at a Glance

55 actively recruiting trials for colorectal cancer (crc) are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 2 with 21 trials, with the heaviest enrollment activity in San Antonio, Fairfax, and Houston. Lead sponsors running colorectal cancer (crc) studies include The First Affiliated Hospital of Nanchang University, Revolution Medicines, Inc., and Fudan University.

Browse colorectal cancer (crc) trials by phase

Treatments under study

About Colorectal Cancer (CRC) Clinical Trials

Looking for clinical trials for Colorectal Cancer (CRC)? There are currently 43 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colorectal Cancer (CRC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colorectal Cancer (CRC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 55 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347
Recruiting
Phase 2

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting

Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)

Metastatic Colorectal Cancer (CRC)
Niguarda Hospital250 enrolled1 locationNCT07536113
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 2

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
The Methodist Hospital Research Institute50 enrolled1 locationNCT07042685
Recruiting
Phase 3

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Summit Therapeutics600 enrolled54 locationsNCT07228832
Recruiting

Advanced Therapies for Liver Metastases

Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Liver Metastasis+1 more
IRCCS San Raffaele625 enrolled1 locationNCT04622423
Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled5 locationsNCT07397338
Recruiting
Phase 1

Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Ying Yuan, MD20 enrolled1 locationNCT07504523
Recruiting
Phase 1Phase 2

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Colorectal Cancer (CRC)Metastatic Colorectal Carcinoma (mCRC)Adenomatous Polyposis Coli (APC) Gene Mutation+1 more
HonorHealth Research Institute126 enrolled1 locationNCT07463599
Recruiting
Phase 2

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor+1 more
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06895031
Recruiting
Phase 2

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

Colorectal Cancer (CRC)
Sun Yat-sen University50 enrolled1 locationNCT07448142
Recruiting
Phase 1

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Not Applicable

Reduce Sedentary Behavior During Cancer Treatment - the RedSedCan Study

Breast CancerProstate CancerNeoadjuvant Therapy+2 more
Mälardalen University172 enrolled2 locationsNCT06719206
Recruiting
Phase 1Phase 2

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

Squamous Cell Carcinoma of Head and NeckSolid TumorColorectal Cancer (CRC)
One-carbon Therapeutics AB43 enrolled4 locationsNCT07151040
Recruiting

Faecal Immunochemical Tests (FIT) for Surveillance After Colorectal Cancer (CRC) Study

Colorectal Cancer (CRC)
Nottingham University Hospitals NHS Trust1,000 enrolled1 locationNCT06689293
Recruiting
Phase 3

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Shanghai Zhongshan Hospital144 enrolled1 locationNCT07309289
Recruiting
Phase 3

mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC

Colorectal Cancer (CRC)pMMR/MSS Adenocarcinoma of the Colon or Rectum
Jun Huang166 enrolled1 locationNCT06791512
Recruiting

Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer

Neoadjuvant TherapyColorectal Cancer (CRC)Proteomics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences400 enrolled1 locationNCT06904677
Recruiting

Examination of the Large Intestine With Camera Capsule in Patients With Blood Stream Infection With Gut-associated Bacteria

Colorectal Cancer (CRC)Colorectal Cancer and Pre-cancer PolypsBlood Stream Infection+2 more
Odense University Hospital100 enrolled1 locationNCT06919068